Comparative Pharmacology
Head-to-head clinical analysis: AMBODRYL versus TRIPROLIDINE HYDROCHLORIDE PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBODRYL versus TRIPROLIDINE HYDROCHLORIDE PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
AMBODRYL vs TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine (H1-receptor antagonist) with anticholinergic and sedative properties.
Triprolidine is a first-generation antihistamine that competes with histamine for H1-receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a nasal decongestant via alpha-adrenergic receptor activation, causing vasoconstriction. Codeine is an opioid agonist at mu-opioid receptors, producing antitussive effects by suppressing the cough center in the medulla.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed, up to a maximum of 80 mg/day.
Each 5 mL oral solution contains triprolidine HCl 1.25 mg, pseudoephedrine HCl 30 mg, and codeine phosphate 10 mg. Adult dose: 10 mL (2 teaspoonfuls) every 4 to 6 hours, not to exceed 40 mL in 24 hours.
None Documented
None Documented
Terminal elimination half-life 12-15 hours in adults; prolonged to 20-30 hours in hepatic impairment.
Triprolidine: 3-6 hours (increased in elderly). Pseudoephedrine: 5-8 hours (prolonged with alkaline urine; up to 16 hours at pH 8). Codeine: 2.5-3.5 hours (terminal half-life; morphine metabolite ~2-3 hours).
Primarily renal (70-80% as metabolites, 20-30% unchanged); biliary/fecal excretion accounts for 15-20%.
Triprolidine: predominantly renal (85% as metabolites, <5% unchanged). Pseudoephedrine: renal (70-90% unchanged, dependent on urine pH). Codeine: renal (86% total, 5-15% unchanged, rest as conjugates and metabolites including morphine).
Category C
Category A/B
Antihistamine
Antihistamine